Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study

Polaris Group, announced that the first patient was successfully dosed in the Phase 2a clinical study for Non-Alcoholic Steatohepatitis.